Home›Research›Compare›Cagrilintide vs Tesamorelin
Peptide ComparisonCagrilintide vs Tesamorelin
Cagrilintide
AM833
Half-life: ~7 days
20 providers listed
Tesamorelin
Egrifta
Half-life: 26–38 minutes
242 providers listed
Cagrilintide and Tesamorelin target different goals — Cagrilintide for Metabolic, Tesamorelin for FDA-approved GHRH analog for HIV-associated lipodystrophy (Egrifta / Egrifta SV). They're compared here for reference, not as direct substitutes.
Cagrilintide
Evidence
Half-life
~7 days
Tesamorelin
Evidence
Half-life
26–38 minutes
Cagrilintide and Tesamorelin target different goals — Cagrilintide for Metabolic, Tesamorelin for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.
Cagrilintide
Tesamorelin
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+6 more
Tesamorelin
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with exce…
Effects of tesamorelin in HIV-infected patients with excess abdominal fat: pooled analysis of two phase 3 RCTs
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
Combined antiretroviral therapy with low- or normal-protein, high-calorie diets appears to induce significant…
+3 more
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Tesamorelin
Tesamorelin stimulates pulsatile GH secretion from the anterior pituitary by binding GHRH receptors. Its stabilisation protects it from rapid enzymatic cleavage by dipeptidyl peptidase IV, extending the effective half-life compared to unmodified GHRH. Downstream effects on visceral adiposity are mediated through elevated IGF-1 and direct lipolytic signalling.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Tesamorelin
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceCagrilintide
Tesamorelin
Where to source these peptides
Cagrilintide
20 listed
Browse directory →
Providers offeringTesamorelin
242 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
Related Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 22, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Tesamorelin — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/tesamorelin